Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022]

Absolute Antibody

Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022]

7

This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Bates et al. 2021 (PMID: 32766589) used CR3022 in a immunofluorescence assay.

ImmunoFluorescence, ELISA, Neutralisation/Blocking, Other Application

ELISA; NTRL; SPR; Crystallography; IF

Research Use Only

Spike glycoprotein

This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

-20°C,2°C to 8°C

12352203